Page 1

Aarkstore.in | VEGF Inhibition: Therapy-Indicating and


Summary: Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer. While VEGF inhibitors such as bevacizumab (Avastin速) provide valuable treatment options, these benefits are not seen in all patients and cancer types. Today, there is an urgent need for predictive biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report (see brochure) provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin速); both therapy-indicating and prognostic. The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic therapy is in its early stages, however important advances have been made. This report identifies the latest findings on ten different cancers and includes an evaluation of candidate biomarkers as a basis for interpreting patient outcomes according to RECIST criteria, and evaluates existing bevacizumab-containing treatments and drug combinations.


Table of Contents: Chapter 1: Background (p.18) 1.1 VEGF Inhibition 1.2 Bevacizumab 1.3 Biomarkers 1.4 This Report Chapter 2 Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies (p. 22) Summary 2.1 Introduction 2.2 Glycoprotein 2.3 Protein 2.4 Protein 2.5 Cells 2.6 Genetic 2.7 Physical 2.8 Genetic 2.9 Protein 2.10 Proteins


More Related Reports : •

VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011

Biomarkers in Alzheimers Disease, 2011

Alzheimers Disease: Autoantibodies, Vaccines and Therapeutic Antibodies Pipelin •

Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011

Image-Based Biomarkers in Alzheimers Disease, 2011

Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical


For More details: http://www.aarkstore.com/reports/VEGF-Inhibition-Therapy-Indicatingand-Prognostic-Biomarkers-2011-154228.html Vina Aarkstore.com Mob.No.918149852585 Email: enquiry@aarkstore.com URL: http://www.aarkstore.in/

Aarkstore.com - VEGF Inhibition - Therapy-Indicating and Prognostic Biomarkers, 2011